Clik here to view.
TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients...
BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) today announced that the new dosing regimen for TURALIO® (pexidartinib) is now available in the U.S. for the treatment of adult patients with...
View ArticleClik here to view.
武田薬品工業: パイプラインの進展と2つのターゲットを絞った取得案件により長期的成長に向け加速、2022年度第3四半期も力強い業績を達成
大阪 （ビジネスワイヤ） – 武田薬品工業株式会社（TOKYO:4502/NYSE:TAK）は、本日、2022年度第3四半期の業績を公表しましたのでお知らせします。 当社チーフ フィナンシャル オフィサーのコスタ・サルウコス（Costa Saroukos）は次のように述べています。...
View ArticleClik here to view.
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two...
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022). Takeda chief financial officer, Costa...
View ArticleClik here to view.
New Talk About It Resources Aim to Accelerate Integration of Mental Health...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer...
View ArticleClik here to view.
Exscientia宣布对百时美施贵宝许可的PKC Theta抑制剂EXS4318进行首次人体研究
英格兰牛津 (美国商业资讯)–EXS4318 (’4318)是一种由Exscientia plc (Nasdaq: EXAI)设计并由百时美施贵宝(Bristol Myers...
View ArticleClik here to view.
エクセンシア、ブリストル マイヤーズ スクイブにライセンスしたPKCシータ阻害剤EXS4318のヒト初回投与試験の開始を発表
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は本日、当社が精密設計し、2021年8月にブリストル マイヤーズ スクイブにライセンスした化合物EXS4318（’4318）の第1相臨床試験が米国で開始されたと発表しました。本化合物は、免疫・炎症領域（I&I）の適応症で開発が進行中です。ブリストル マイヤーズ...
View ArticleClik here to view.
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by...
BEIJING American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia...
View ArticleClik here to view.
武田通过推进管线建设和两项针对性收购加强长期增长；2022财年第三季度再次实现强劲业绩
日本大阪 (美国商业资讯)–武田(TOKYO:4502/NYSE:TAK)今天公布了2022财年第三季度（截至2022年12月31日）的财务业绩。 武田首席财务官Costa Saroukos评论道：...
View ArticleClik here to view.
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC...
View ArticleClik here to view.
武田完成对Nimbus Therapeutics旗下TYK2项目子公司的收购
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，正如股份购买协议所述，在获得美国联邦贸易委员会的许可和满足其他成交条件后，公司已于美国东部标准时间2023年2月8日完成了从Nimbus Therapeutics, LLC (“Nimbus”)手中收购Nimbus Lakshmi, Inc....
View ArticleClik here to view.
Clik here to view.
LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From...
DAEJEON, South Korea LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter “LegoChemBio”) announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland,...
View ArticleClik here to view.
GI Dynamics Announces First Patient Enrolled in the I-STEP Clinical Study of...
BOSTON & HYDERABAD, India GI Dynamics® Inc., a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce...
View ArticleClik here to view.
Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND...
SEOUL, South Korea Lemonex Inc., a biotechnology company pioneering messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 14h of February...
View ArticleClik here to view.
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating...
CAMBRIDGE, Mass. VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data...
View ArticleClik here to view.
TAE Life Sciences Announces First Cancer Patient Treatments Using...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that the first...
View ArticleClik here to view.
U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute...
View ArticleClik here to view.
LevitasBio推出LeviSelect细胞去除和富集试剂盒套装
加州门罗帕克 (美国商业资讯)–生命科学市场领先的端到端样本处理和细胞分析提供商LevitasBio, Inc. (www.levitasbio.com)推出用于免疫学研究的LeviSelect™细胞去除和富集试剂盒套装。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20230207005652/zh-CN/ Five...
View ArticleClik here to view.
レビタスバイオがLeviSelect細胞除去・濃縮キット一式を発売
米カリフォルニア州メンロパーク （ビジネスワイヤ） — ライフサイエンス市場にエンドツーエンドの試料処理・細胞分析サービスを提供する一流企業のレビタスバイオ（www.levitasbio.com）は、免疫研究用のLeviSelect™細胞除去・濃縮キット一式を発表します。...
View ArticleClik here to view.
Exscientia将参加即将于3月召开的多场投资者会议
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天宣布，公司管理层将于3月份出席以下投资者会议： 摩根士丹利欧洲、中东和非洲健康技术大会。管理层将于2023年3月1日（周三）参加线上投资者会议...
View Article